<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="http://www.fda.gov/oc/datacouncil/stylesheets/spl/spl.xsl" type="text/xsl"?><document xmlns="urn:hl7-org:v3" xmlns:voc="http://www.hl7.org/v3/voc" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.fda.gov/oc/datacouncil/schemas/spl/spl.xsd">
<id root="4BD8FAA3-CB8E-45FB-E280-6DF688DDC3A9" />
<code code="34391-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Human Prescription Drug Label" />
<title mediaType="text/x-hl7-title+xml">PROSOM&#8482;<br /> 	(estazolam tablets)<br />CS-IV</title>
<effectiveTime value="20060616" />
<setId root="4BD8FAA3-CB8E-45FB-E280-6DF688DDC3A9" />
<versionNumber value="1" />
<author>
<time />
<assignedEntity>
<representedOrganization>
<name>Abbott Laboratories</name>
</representedOrganization>
</assignedEntity>
</author>
<component>
<structuredBody>
<component>
<section>
<id root="5F2426AC-AB01-C116-AE5D-FA0B95B293FA" />
<effectiveTime value="20060616" />
<subject>
<manufacturedProduct>
<manufacturedMedicine>
<code code="0074-3735" codeSystem="2.16.840.1.113883.6.69" />
<name>PROSOM</name>
<formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" codeSystemName="FDA DRG 201" displayName="TABLET" />
<activeIngredient>
<quantity>
<numerator unit="mg" value="1">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="1" />
</numerator>
<denominator value="1">
<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="1" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="36S3EQV54C" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>estazolam</name>
<activeMoiety>
<activeMoiety>
<code code="36S3EQV54C" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>estazolam</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<asEntityWithGeneric>
<genericMedicine>
<name>estazolam</name>
</genericMedicine>
</asEntityWithGeneric>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>Colloidal silicon dioxide</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>lactose</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>povidone</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="4ELV7Z65AP" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>stearic acid</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>sodium starch glycolate</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<asContent>
<quantity>
<numerator value="100">
<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="100" />
</numerator>
<denominator value="1">
<translation value="1" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code code="0074-3735-13" codeSystem="2.16.840.1.113883.6.69" codeSystemName="NDC" />
<formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE" />
</containerPackagedMedicine>
</asContent>
</manufacturedMedicine>
<subjectOf>
<policy classCode="DEADrugSchedule">
<code code="C48677" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CIV">
<originalText>IV</originalText>
</code>
</policy>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255" />
<value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLCOATING" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="false" xsi:type="BL" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="2" xsi:type="INT" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255" />
<value xsi:type="ST">UC</value>
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSYMBOL" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="true" xsi:type="BL" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value unit="mm" value="7" xsi:type="PQ" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value code="C48347" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="RECTANGLE" xsi:type="CE" />
</characteristic>
</subjectOf>
<consumedIn>
<substanceAdministration>
<routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL" />
</substanceAdministration>
</consumedIn>
</manufacturedProduct>
</subject>
<subject>
<manufacturedProduct>
<manufacturedMedicine>
<code code="0074-3736" codeSystem="2.16.840.1.113883.6.69" />
<name>PROSOM</name>
<formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" codeSystemName="FDA DRG 201" displayName="TABLET" />
<activeIngredient>
<quantity>
<numerator unit="mg" value="2">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="2" />
</numerator>
<denominator value="1">
<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="1" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="36S3EQV54C" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>estazolam</name>
<activeMoiety>
<activeMoiety>
<code code="36S3EQV54C" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>estazolam</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<asEntityWithGeneric>
<genericMedicine>
<name>estazolam</name>
</genericMedicine>
</asEntityWithGeneric>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>Colloidal silicon dioxide</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>lactose</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>povidone</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="4ELV7Z65AP" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>stearic acid</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>sodium starch glycolate</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>FD&amp;C Red No. 40</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<asContent>
<quantity>
<numerator value="100">
<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="100" />
</numerator>
<denominator value="1">
<translation value="1" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code code="0074-3736-13" codeSystem="2.16.840.1.113883.6.69" codeSystemName="NDC" />
<formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE" />
</containerPackagedMedicine>
</asContent>
</manufacturedMedicine>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255" />
<value code="C48328" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PINK" xsi:type="CE" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLCOATING" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="false" xsi:type="BL" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="2" xsi:type="INT" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255" />
<value xsi:type="ST">UD</value>
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value unit="mm" value="7" xsi:type="PQ" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value code="C48347" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="RECTANGLE" xsi:type="CE" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSYMBOL" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="true" xsi:type="BL" />
</characteristic>
</subjectOf>
<consumedIn>
<substanceAdministration>
<routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL" />
</substanceAdministration>
</consumedIn>
</manufacturedProduct>
</subject>
</section>
</component>
<component>
<section>
<id root="5D9FC855-9767-B9E5-F3A5-82C784A662D1" />
<code code="34089-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DESCRIPTION section" />
<title mediaType="text/x-hl7-title+xml">DESCRIPTION</title>
<text><paragraph>ProSom (estazolam), a triazolobenzodiazepine derivative,
is an oral hypnotic agent.  Estazolam occurs as a fine, white, odorless powder
that is soluble in alcohol and practically insoluble in water.  The chemical
name for estazolam is 8&#8722;chloro&#8722;6&#8722;phenyl&#8722;4H&#8722;s&#8722;triazolo[4,3-&#945;]&#160;[1,4]benzodiazepine.
 The empirical formula is C<sub>16</sub>H<sub>11</sub>ClN<sub>4</sub>.  The
structural formula is represented as follows:</paragraph><paragraph><renderMultiMedia referencedObject="MM1131659841-1" /></paragraph><paragraph>ProSom tablets are scored and contain either
1 mg or 2 mg of estazolam.</paragraph></text>
<effectiveTime value="20060616" />
<component>
<section>
<id root="B10DB8EE-9BF9-5A78-4B84-D36C5F822866" />
<title mediaType="text/x-hl7-title+xml">Inactive Ingredients</title>
<text><paragraph>Colloidal silicon dioxide, lactose, povidone, stearic
acid, and sodium starch glycolate.</paragraph><paragraph>In addition,
the 2 mg tablets contain FD&amp;C Red No. 40.</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
<component>
<observationMedia ID="MM1131659841-1">
<id root="B73763C6-54A2-4FA0-E4B1-966930BCF1C1" />
<value mediaType="image/jpeg" xsi:type="ED"><reference value="prosom-structure.jpg" /></value>
</observationMedia>
</component>
</section>
</component>
<component>
<section>
<id root="AD743D2A-9778-949C-F093-9FC0C43319BC" />
<code code="34090-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CLINICAL PHARMACOLOGY section" />
<title mediaType="text/x-hl7-title+xml">CLINICAL PHARMACOLOGY</title>
<text />
<effectiveTime value="20060616" />
<component>
<section>
<id root="6AAF1699-50B8-FB78-B4A8-88DF4A7D0C17" />
<title mediaType="text/x-hl7-title+xml">Pharmacokinetics</title>
<text><paragraph /></text>
<effectiveTime value="20060616" />
<component>
<section>
<id root="B584FCD2-7293-1331-2AB9-2BFF023F4547" />
<title mediaType="text/x-hl7-title+xml">Absorption</title>
<text><paragraph>ProSom tablets have been found to be equivalent
in absorption to an orally administered solution of estazolam.  In healthy
subjects who received up to three times the recommended dose of ProSom, peak
estazolam plasma concentrations occurred within two hours after dosing (range
0.5 to 6.0 hours) and were proportional to the administered dose, suggesting
linear pharmacokinetics over the dosage range tested.</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
<component>
<section>
<id root="EA6DF483-CD29-F625-FB4B-634F48101D70" />
<title mediaType="text/x-hl7-title+xml">Distribution</title>
<text><paragraph>Independent of concentration, estazolam in plasma
is 93% protein bound.</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
<component>
<section>
<id root="2419DD46-7BC6-31FA-3B9F-35C4C5CA66FA" />
<title mediaType="text/x-hl7-title+xml">Metabolism</title>
<text><paragraph>Estazolam is extensively metabolized.  Only two
metabolites (1-oxo-estazolam &amp; 4&#160;&#8722;&#160;hydroxy&#160;&#8722;&#160;estazolam)
were detected in human plasma up to 18 hrs.</paragraph><paragraph>The
pharmacologic activity of estazolam is primarily from the parent drug.  The
elimination of the parent drug takes place via hepatic metabolism of estazolam
to hydroxylated and other metabolites that are eliminated largely in the urine
both free and conjugated.  In humans, greater than 70% of a single dose of
estazolam was recovered in the urine as metabolites.  Less than 5% of a 2
mg dose of estazolam was excreted unchanged in the urine, with only 4% of
the dose appearing in the feces.  The principal urinary excretion product
is an unidentified metabolite, presumed to be a metabolic product of 4-hydroxy-estazolam,
accounting for at least 27% of the administered dose. 4&#160;&#8722;&#160;hydroxy-estazolam
is the major metabolite in plasma, with concentrations approaching 12% of
those of the parent eight hours after administration.  Urinary 4&#160;&#8722;&#160;hydroxy&#160;&#8722;&#160;estazolam
and 1-oxo-estazolam account for 11.9% and 4.4% of the dose respectively.  <content styleCode="italics">In&#160;vitro</content> studies with human liver microsomes
indicate that the biotransformation of estazolam to the major circulating
metabolite 4&#160;&#8722;&#160;hydroxy&#160;&#8722;&#160;estazolam is mediated
by cytochrome P450&#160;3A (CYP3A).  While 4-hydroxy-estazolam and the lesser
metabolite, 1-oxo-estazolam, have some pharmacologic activity, their low potencies
and low concentrations preclude any significant contribution to the hypnotic
effect of ProSom.</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
<component>
<section>
<id root="A49CBF60-461B-1E31-2E53-71246443592F" />
<title mediaType="text/x-hl7-title+xml">Elimination</title>
<text><paragraph>The range of estimates for the mean elimination
half-life of estazolam varied from 10 to 24 hours.  Radiolabel mass balance
studies indicate that the main route of excretion is via the kidneys.  After
5 days, 87% of the administered radioactivity was excreted in human urine.
 Less than 4% of the dose was excreted unchanged.  Eleven metabolites were
found in urine.  Four metabolites were identified as 1-oxo-estazolam, 4'&#160;&#8722;&#160;hydroxy&#160;&#8722;&#160;estazolam,
4-hydroxy-estazolam, and benzophenone, as free metabolites and glucuronides.
 The predominant metabolite in urine (17% of the administered dose) has not
been identified, but is likely to be a metabolite of 4-hydroxy-estazolam.</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
<component>
<section>
<id root="E2F6877C-703F-5A0D-8D52-30D9919E33F8" />
<title mediaType="text/x-hl7-title+xml">Special Populations</title>
<text><paragraph>In a small study (N=8) using various doses in
older subjects (59 to 68 years), peak estazolam concentrations were found
to be similar to those observed in younger subjects with a mean elimination
half-life of 18.4 hours (range 13.5 to 34.6 hours).  The influence of hepatic
or renal impairment on the pharmacokinetics of estazolam has not been studied.</paragraph></text>
<effectiveTime value="20060616" />
<component>
<section>
<id root="FD8BDE1A-6DD6-BA49-9533-865198C5C06A" />
<title mediaType="text/x-hl7-title+xml">Pediatrics</title>
<text><paragraph>The pharmacokinetics of estazolam have not been
studied in pediatric patients.</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
<component>
<section>
<id root="58ECABD6-38D9-FC37-2573-04D536F17146" />
<title mediaType="text/x-hl7-title+xml">Race</title>
<text><paragraph>The influence of race on the pharmacokinetics
of estazolam has not been studied.</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
<component>
<section>
<id root="38EB965F-DA79-FA0C-8AAC-778547AFC54F" />
<title mediaType="text/x-hl7-title+xml">Gender</title>
<text><paragraph>The gender-effect on the pharmacokinetics of
estazolam has not been investigated.</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
<component>
<section>
<id root="F354B349-8FF8-9BE0-A958-5330CB7652B3" />
<title mediaType="text/x-hl7-title+xml">Cigarette Smoking</title>
<text><paragraph>The clearance of benzodiazepines is accelerated
in smokers compared to nonsmokers, and there is evidence that this occurs
with estazolam.  This decrease in half-life, presumably due to enzyme induction
by smoking, is consistent with other drugs with similar hepatic clearance
characteristics.  In all subjects and at all doses, the mean elimination half-life
appeared to be independent of the dose.</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
</section>
</component>
<component>
<section>
<id root="2EA2A7FF-C129-E3F8-CA55-003787E5A1F7" />
<title mediaType="text/x-hl7-title+xml">Drug-Drug Interaction</title>
<text><paragraph>The metabolism of estazolam to the major circulating
metabolite 4-hydroxy-estazolam is catalyzed by CYP3A.  While no <content styleCode="italics">in&#160;vivo </content> drug-drug interaction studies were conducted between estazolam
and inhibitors/inducers of CYP3A, compounds that are potent CYP3A inhibitors
(such as ketoconazole, itraconazole, nefazodone, fluvoxamine, and erythromycin)
would be expected to increase plasma estazolam concentrations and CYP3A inducers
(such as carbamazepine, phenytoin, rifampin and barbiturates) would be expected
to decrease estazolam concentrations.</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
<component>
<section>
<id root="105D794D-2922-0ABD-A949-B6D4472C44DD" />
<title mediaType="text/x-hl7-title+xml">Drug Interaction with Fluoxetine</title>
<text><paragraph>A multiple-dose study was conducted to assess
the effect of fluoxetine 20 mg BID on the pharmacokinetics of estazolam 2
mg QHS after seven days.  The pharmacokinetics of estazolam (C<sub>max</sub> and
AUC) were not affected during multiple-dose fluoxetine, suggesting no clinically
significant pharmacokinetic interaction.</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
<component>
<section>
<id root="7DA54EE6-9D18-E490-32B9-D8F264649A60" />
<title mediaType="text/x-hl7-title+xml">The Ability of Estazolam to Induce or Inhibit Human Enzyme Systems</title>
<text><paragraph>The results from <content styleCode="italics">in&#160;vitro </content> human liver microsomal studies suggest that at therapeutic concentrations,
estazolam has no significant inhibitory effect on the major human cytochrome
P450 enzyme activities (i.e., CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1,
and CYP3A).  The ability of estazolam to induce human hepatic enzyme systems
has not been determined.</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
</section>
</component>
<component>
<section>
<id root="63EF1432-67C8-6D38-7E20-26E115293409" />
<title mediaType="text/x-hl7-title+xml">Pharmacodynamics</title>
<text><paragraph /></text>
<effectiveTime value="20060616" />
<component>
<section>
<id root="7BDEE5D7-860D-3E7D-41B7-0C9FCC4FE179" />
<title mediaType="text/x-hl7-title+xml">Postulated relationship between elimination rate of benzodiazepine
hypnotics and their profile of common untoward effects</title>
<text><paragraph>The type and duration of hypnotic effects and
the profile of unwanted effects during administration of benzodiazepine drugs
may be influenced by the biologic half-life of administered drug and any active
metabolites formed.  If half-lives are long, drug or metabolites may accumulate
during periods of nightly administration and may be associated with impairments
of cognitive and/or motor performance during waking hours; the possibility
of interaction with other psychoactive drugs or alcohol will be increased.
 In contrast, if half-lives are short, drug and metabolites will be cleared
before the next dose is ingested, and carry-over effects related to excessive
sedation or CNS depression should be minimal or absent.  However, during nightly
use for an extended period, pharmacodynamic tolerance or adaptation to some
effects of benzodiazepine hypnotics may develop.  If the drug has a short
elimination half-life, it is possible that a relative deficiency of the drug
or its active metabolites (i.e.,&#160;in relationship to the receptor site)
may occur at some point in the interval between each night's use.  This
sequence of events may account for two clinical findings reported to occur
after several weeks of nightly use of rapidly eliminated benzodiazepine hypnotics,
namely, increased wakefulness during the last third of the night and increased
daytime anxiety in selected patients.</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
</section>
</component>
</section>
</component>
<component>
<section>
<id root="54678A78-1A81-E98D-C0F9-D2F392926377" />
<code code="34092-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CLINICAL STUDIES section" />
<title mediaType="text/x-hl7-title+xml">CLINICAL STUDIES</title>
<text />
<effectiveTime value="20060616" />
<component>
<section>
<id root="04E9B2B8-B69F-0795-2242-9417FEF3DD88" />
<title mediaType="text/x-hl7-title+xml">Controlled Trials Supporting Efficacy</title>
<text><paragraph>In three 7-night, double-blind, parallel-group trials
comparing estazolam 1 mg and/or 2&#160;mg with placebo in adult outpatients
with chronic insomnia, estazolam 2 mg was consistently superior to placebo
in subjective measures of sleep induction (latency) and sleep maintenance
(duration, number of awakenings, depth and quality of sleep); estazolam 1
mg was similarly superior to placebo on all measures of sleep maintenance,
however, it significantly improved sleep induction in only one of two studies.
 In a similarly designed trial comparing estazolam 0.5 mg and 1 mg with placebo
in geriatric outpatients with chronic insomnia, only the 1 mg estazolam dose
was consistently superior to placebo in sleep induction (latency) and in only
one measure of sleep maintenance (i.e., duration of sleep).</paragraph><paragraph>In a single-night, double-blind, parallel-group trial comparing
estazolam 2&#160;mg and placebo in patients admitted for elective surgery
and requiring sleep medications, estazolam was superior to placebo in subjective
measures of sleep induction and maintenance.</paragraph><paragraph>In
a 12-week, double-blind, parallel-group trial including a comparison of estazolam
2&#160;mg and placebo in adult outpatients with chronic insomnia, estazolam
was superior to placebo in subjective measures of sleep induction (latency)
and maintenance (duration, number of awakenings, total wake time during sleep)
at Week 2, but produced consistent improvement over 12 weeks only for sleep
duration and total wake time during sleep.  Following withdrawal at Week 12,
rebound insomnia was seen at the first withdrawal week, but there was no difference
between drug and placebo by the second withdrawal week in all parameters except
latency, for which normalization did not occur until the fourth withdrawal
week.</paragraph><paragraph>Adult outpatients with chronic insomnia
were evaluated in a sleep laboratory trial comparing four doses of estazolam
(0.25, 0.50, 1.0 and 2.0 mg) and placebo, each administered for 2 nights in
a crossover design.  The higher estazolam doses were superior to placebo in
most EEG measures of sleep induction and maintenance, especially at the 2
mg dose, but only for sleep duration in subjective measures of sleep.</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
</section>
</component>
<component>
<section>
<id root="C8EC5AEC-FB18-A1AE-09E4-334DD3B4466C" />
<code code="34067-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="INDICATIONS AND USAGE section" />
<title mediaType="text/x-hl7-title+xml">INDICATIONS AND USAGE</title>
<text><paragraph>ProSom (estazolam) is indicated for the short-term
management of insomnia characterized by difficulty in falling asleep, frequent
nocturnal awakenings, and/or early morning awakenings.  Both outpatient studies
and a sleep laboratory study have shown that ProSom administered at bedtime
improved sleep induction and sleep maintenance (see <content styleCode="bold">CLINICAL
PHARMACOLOGY</content>).</paragraph><paragraph>Because insomnia is
often transient and intermittent, the prolonged administration of ProSom is
generally neither necessary nor recommended.  Since insomnia may be a symptom
of several other disorders, the possibility that the complaint may be related
to a condition for which there is a more specific treatment should be considered.</paragraph><paragraph>There is evidence to support the ability of ProSom to enhance
the duration and quality of sleep for intervals up to 12 weeks (see <content styleCode="bold">CLINICAL PHARMACOLOGY</content>).</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
<component>
<section>
<id root="A71AEAE7-EF58-F1FE-277B-FDD8746AC8E5" />
<code code="34070-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CONTRAINDICATIONS section" />
<title mediaType="text/x-hl7-title+xml">CONTRAINDICATIONS</title>
<text><paragraph>Benzodiazepines may cause fetal damage when administered
during pregnancy.  An increased risk of congenital malformations associated
with the use of diazepam and chlordiazepoxide during the first trimester of
pregnancy has been suggested in several studies.  Transplacental distribution
has resulted in neonatal CNS depression and also withdrawal phenomena following
the ingestion of therapeutic doses of a benzodiazepine hypnotic during the
last weeks of pregnancy.</paragraph><paragraph>ProSom is contraindicated
in pregnant women.  If there is a likelihood of the patient becoming pregnant
while receiving ProSom she should be warned of the potential risk to the fetus
and instructed to discontinue the drug prior to becoming pregnant.  The possibility
that a woman of childbearing potential is pregnant at the time of institution
of therapy should be considered.</paragraph><paragraph>Estazolam is
contraindicated with ketoconazole and itraconazole, since these medications
significantly impair oxidative metabolism mediated by CYP3A (see <content styleCode="bold">WARNINGS</content> and <content styleCode="bold">PRECAUTIONS
- Drug Interactions</content>).</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
<component>
<section>
<id root="FAF0FE01-9934-FB60-1A60-6A7C34A632D8" />
<code code="34071-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="WARNINGS section" />
<title mediaType="text/x-hl7-title+xml">WARNINGS</title>
<text><paragraph>ProSom, like other benzodiazepines, has CNS depressant
effects.  For this reason, patients should be cautioned against engaging in
hazardous occupations requiring complete mental alertness, such as operating
machinery or driving a motor vehicle, after ingesting the drug, including
potential impairment of the performance of such activities that may occur
the day following ingestion of ProSom.  Patients should also be cautioned
about possible combined effects with alcohol and other CNS depressant drugs.</paragraph><paragraph>As with all benzodiazepines, amnesia, paradoxical reactions
(e.g,, excitement, agitation, etc.), and other adverse behavioral effects
may occur unpredictably.</paragraph><paragraph>There have been reports
of withdrawal signs and symptoms of the type associated with withdrawal from
CNS depressant drugs following the rapid decrease or the abrupt discontinuation
of benzodiazepines (see <content styleCode="bold">DRUG ABUSE AND DEPENDENCE </content>).</paragraph></text>
<effectiveTime value="20060616" />
<component>
<section>
<id root="9F7F6D6E-0168-5984-4C5B-6F30664396F8" />
<title mediaType="text/x-hl7-title+xml">Estazolam Interaction with Drugs that Inhibit Metabolism via Cytochrome
P450 3A (CYP3A)</title>
<text><paragraph>The metabolism of estazolam to the major circulating
metabolite 4-hydroxy-estazolam and the metabolism of other triazolobenzodiazepines
is catalyzed by CYP3A.  Consequently, estazolam should be avoided in patients
receiving ketoconazole and itraconazole, which are very potent inhibitors
of CYP3A (see C<content styleCode="bold">ONTRAINDICATIONS</content>).  With
drugs inhibiting CYP3A to a lesser, but still significant degree, estazolam
should be used only with caution and consideration of appropriate dosage reduction.
 The following are examples of drugs known to inhibit the metabolism of other
related benzodiazepines, presumably through inhibition of CYP3A:  nefazodone,
fluvoxamine, cimetidine, diltiazem, isoniazide, and some macrolide antibiotics.</paragraph><paragraph>While no <content styleCode="italics">in&#160;vivo</content> drug-drug
interaction studies were conducted between estazolam and inducers of CYP3A,
compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin,
rifampin, and barbiturates) would be expected to decrease estazolam concentrations.</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
</section>
</component>
<component>
<section>
<id root="BB17BA4D-A746-F637-CAD4-0FEA1B3B4B1A" />
<code code="42232-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Precautions" />
<title mediaType="text/x-hl7-title+xml">PRECAUTIONS</title>
<text />
<effectiveTime value="20060616" />
<component>
<section>
<id root="308F9A87-D958-C470-5040-0182B486C410" />
<code code="34072-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="GENERAL PRECAUTIONS section" />
<title mediaType="text/x-hl7-title+xml">General</title>
<text><paragraph>Impaired motor and/or cognitive performance attributable
to the accumulation of benzodiazepines and their active metabolites following
several days of repeated use at their recommended doses is a concern in certain
vulnerable patients (e.g., those especially sensitive to the effects of benzodiazepines
or those with a reduced capacity to metabolize and eliminate them) (see <content styleCode="bold">DOSAGE AND ADMINISTRATION</content>).</paragraph><paragraph>Elderly or debilitated patients and those with impaired renal
or hepatic function should be cautioned about these risks and advised to monitor
themselves for signs of excessive sedation or impaired conditions.</paragraph><paragraph>ProSom appears to cause dose-related respiratory depression
that is ordinarily not clinically relevant at recommended doses in patients
with normal respiratory function.  However, patients with compromised respiratory
function may be at risk and should be monitored appropriately.  As a class,
benzodiazepines have the capacity to depress respiratory drive; there are
insufficient data available, however, to characterize their relative potency
in depressing respiratory drive at clinically recommended doses.</paragraph><paragraph>As with other benzodiazepines, ProSom should be administered
with caution to patients exhibiting signs or symptoms of depression.  Suicidal
tendencies may be present in such patients and protective measures may be
required.  Intentional overdosage is more common in this group of patients;
therefore, the least amount of drug that is feasible should be prescribed
for the patient at any one time.</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
<component>
<section>
<id root="7E621995-9F0D-5DB1-250C-DA995F49D690" />
<code code="34076-0" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Information for Patients section" />
<title mediaType="text/x-hl7-title+xml">Information for Patients</title>
<text><paragraph>To assure the safe and effective use of ProSom,
the following information and instructions should be given to patients:</paragraph><list listType="ordered" styleCode="Arabic"><item>Inform your physician about any alcohol consumption and medicine you
are taking now, including drugs you may buy without a prescription.  Alcohol
should not be used during treatment with hypnotics.</item><item>Inform your physician if you are planning to become pregnant, if you
are pregnant, or if you become pregnant while you are taking this medicine.</item><item>You should not take this medicine if you are nursing, as the drug may
be excreted in breast milk.</item><item>Until you experience the way this medicine affects you, do not drive
a car, operate potentially dangerous machinery, or engage in hazardous occupations
requiring complete mental alertness after taking this medicine.</item><item>Since benzodiazepines may produce psychological and physical dependence,
you should not increase the dose before consulting your physician.  In addition,
since the abrupt discontinuation of ProSom may be associated with temporary
sleep disturbances, you should consult your physician before abruptly discontinuing
doses of 2 mg per night or more.</item></list></text>
<effectiveTime value="20060616" />
</section>
</component>
<component>
<section>
<id root="F124049A-0E62-E567-EC7C-ED57558B43F1" />
<code code="34075-2" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Laboratory Tests section" />
<title mediaType="text/x-hl7-title+xml">Laboratory Tests</title>
<text><paragraph>Laboratory tests are not ordinarily required in
otherwise healthy patients.  When treatment with ProSom is protracted, periodic
blood counts, urinalyses, and blood chemistry analyses are advisable.</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
<component>
<section>
<id root="1D14EC8F-2D42-08AD-FD49-82F3DE382A91" />
<code code="34073-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Drug Interactions section" />
<title mediaType="text/x-hl7-title+xml">Drug Interactions</title>
<text><paragraph>If ProSom is given concomitantly with other drugs
acting on the central nervous system, careful consideration should be given
to the pharmacology of all agents.  The action of the benzodiazepines may
be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates,
monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications,
or other drugs that produce CNS depression.  Smokers have an increased clearance
of benzodiazepines as compared to nonsmokers; this was seen in studies with
estazolam (see <content styleCode="bold">CLINICAL PHARMACOLOGY</content>).</paragraph><paragraph>While no <content styleCode="italics">in&#160;vivo</content> drug-drug
interaction studies were conducted between estazolam and inducers of CYP3A,
compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin,
rifampin, and barbiturates) would be expected to decrease estazolam concentrations.</paragraph></text>
<effectiveTime value="20060616" />
<component>
<section>
<id root="076CCC90-EBFD-7B63-B773-B33FBB67F133" />
<title mediaType="text/x-hl7-title+xml">Estazolam Interaction with Drugs that Inhibit Metabolism via Cytochrome
P450 3A (CYP3A)</title>
<text><paragraph>The metabolism of estazolam to the major circulating
metabolite 4-hydroxy-estazolam and the metabolism of other triazolobenzodiazepines
is catalyzed by CYP3A.  Consequently, estazolam should be avoided in patients
receiving ketoconazole and itraconazole, which are very potent inhibitors
of CYP3A (see <content styleCode="bold">CONTRAINDICATIONS</content>).  With
drugs inhibiting CYP3A to a lesser, but still significant degree, estazolam
should be used only with caution and consideration of appropriate dosage reduction.
 The following are examples of drugs known to inhibit the metabolism of other
related benzodiazepines, presumably through inhibition of CYP3A:  nefazodone,
fluvoxamine, cimetidine, diltiazem, isoniazide, and some macrolide antibiotics.</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
<component>
<section>
<id root="749FADCC-546D-47CB-ACE3-986909CE3572" />
<title mediaType="text/x-hl7-title+xml">Drug Interaction with Fluoxetine</title>
<text><paragraph>A multiple-dose study was conducted to assess
the effect of fluoxetine 20 mg BID on the pharmacokinetics of estazolam 2
mg QHS after seven days.  The pharmacokinetics of estazolam (C<sub>max</sub> and
AUC) were not affected during multiple-dose fluoxetine, suggesting no clinically
significant pharmacokinetic interaction.</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
<component>
<section>
<id root="18ECF77D-FEC8-5F17-97EF-55306B868A57" />
<title mediaType="text/x-hl7-title+xml">Estazolam Interaction with Other Drugs that are Metabolized by Cytochrome
P450 (CYP)</title>
<text><paragraph>At clinically relevant concentrations, <content styleCode="italics">in&#160;vitro</content> studies indicate that estazolam
(0.6 &#181;M) was not inhibitory towards the major cytochrome P450 isoforms
CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A.  Therefore, based
on these <content styleCode="italics">in&#160;vitro</content> data, estazolam
is very unlikely to inhibit the biotransformation of other drugs metabolized
by these CYP isoforms.</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
</section>
</component>
<component>
<section>
<id root="83CCBEBD-BAC0-7CD9-3962-68D81675FA2A" />
<code code="34083-6" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Carcinogenesis, Mutagenesis, Impairment of Fertility section" />
<title mediaType="text/x-hl7-title+xml">Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
<text><paragraph>Two-year carcinogenicity studies were conducted
in mice and rats at dietary doses of 0.8, 3, and 10 mg/kg/day and 0.5, 2,
and 10 mg/kg/day, respectively.  Evidence of tumorigenicity was not observed
in either study.  Incidence of hyperplastic liver nodules increased in female
mice given the mid- and high-dose levels.  The significance of such nodules
in mice is not known at this time.</paragraph><paragraph><content styleCode="italics">In&#160;vitro</content> and <content styleCode="italics">in&#160;vivo</content> mutagenicity tests including the Ames test, DNA repair in <content styleCode="italics">B.&#160;subtilis</content>, <content styleCode="italics">in&#160;vivo</content> cytogenetics in mice and rats, and the dominant lethal test in
mice did not show a mutagenic potential for estazolam.</paragraph><paragraph>Fertility in male and female rats was not affected by doses up
to 30 times the usual recommended human dose.</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
<component>
<section>
<id root="683A1526-972D-BA56-6152-B32731151D02" />
<code code="42228-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Pregnancy" />
<title mediaType="text/x-hl7-title+xml">Pregnancy</title>
<text><list listType="ordered" styleCode="Arabic"><item>Teratogenic Effects:  Pregnancy Category X (see <content styleCode="bold">CONTRAINDICATIONS</content>).</item><item>Nonteratogenic Effects:  The child born of a mother taking benzodiazepines
may be at some risk for withdrawal symptoms during the postnatal period. 
Neonatal flaccidity has been reported in an infant born of a mother who received
benzodiazepines during pregnancy.</item></list></text>
<effectiveTime value="20060616" />
</section>
</component>
<component>
<section>
<id root="0F654E09-DE53-D935-D8A8-D9F586EA1CDB" />
<code code="34079-4" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Labor and Delivery section" />
<title mediaType="text/x-hl7-title+xml">Labor and Delivery</title>
<text><paragraph>ProSom has no established use in labor or delivery.</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
<component>
<section>
<id root="193F1135-48FA-FA37-594C-EB89C58EB84F" />
<code code="34080-2" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Nursing Mothers section" />
<title mediaType="text/x-hl7-title+xml">Nursing Mothers</title>
<text><paragraph>Human studies have not been conducted; however,
studies in lactating rats indicate that estazolam and/or its metabolites are
secreted in the milk.  The use of ProSom in nursing mothers is not recommended.</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
<component>
<section>
<id root="0D62E079-227F-4C1A-BD67-BB6F287611A2" />
<code code="34081-0" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Pediatric Use section" />
<title mediaType="text/x-hl7-title+xml">Pediatric Use</title>
<text><paragraph>Safety and effectiveness in pediatric patients below
the age of 18 have not been established.</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
<component>
<section>
<id root="A46AF04F-B6B6-4EBB-23E0-3D42F960F6C4" />
<code code="34082-8" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Geriatric Use section" />
<title mediaType="text/x-hl7-title+xml">Geriatric Use</title>
<text><paragraph>Approximately 18% of individuals participating in
the premarketing clinical trials of ProSom were 60 years of age or older.
 Overall, the adverse event profile did not differ substantively from that
observed in younger individuals.  Care should be exercised when prescribing
benzodiazepines to small or debilitated elderly patients (see <content styleCode="bold">DOSAGE
AND ADMINISTRATION</content>).</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
</section>
</component>
<component>
<section>
<id root="92763879-C8ED-25C8-BDBF-157950B093A1" />
<code code="34084-4" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="ADVERSE REACTIONS section" />
<title mediaType="text/x-hl7-title+xml">ADVERSE REACTIONS</title>
<text />
<effectiveTime value="20060616" />
<component>
<section>
<id root="1CEFFB72-19B8-1EAF-7F92-3741A4E0FA6D" />
<title mediaType="text/x-hl7-title+xml">Commonly Observed</title>
<text><paragraph>The most commonly observed adverse events associated
with the use of ProSom, not seen at an equivalent incidence among placebo-treated
patients were somnolence, hypokinesia, dizziness, and abnormal coordination.</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
<component>
<section>
<id root="EFA7EF43-3F06-A7D9-B8D8-E2343AFC9676" />
<title mediaType="text/x-hl7-title+xml">Associated with Discontinuation of Treatment</title>
<text><paragraph>Approximately 3% of 1277 patients who received ProSom
in US premarketing clinical trials discontinued treatment because of an adverse
clinical event.  The only event commonly associated with discontinuation,
accounting for 1.3% of the total, was somnolence.</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
<component>
<section>
<id root="6760A19E-2252-D1A0-4BA2-D26FA43B8B25" />
<title mediaType="text/x-hl7-title+xml">Incidence in Controlled Clinical Trials</title>
<text><paragraph>The table below enumerates adverse events that occurred
at an incidence of 1% or greater among patients with insomnia who received
ProSom in 7-night, placebo-controlled trials.  Events reported by investigators
were classified into standard dictionary (COSTART) terms to establish event
frequencies.  Event frequencies reported were not corrected for the occurrence
of these events at baseline.  The frequencies were obtained from data pooled
across six studies:  ProSom, N=685; placebo, N=433.  The prescriber should
be aware that these figures cannot be used to predict the incidence of side
effects in the course of usual medical practice in which patient characteristics
and other factors differ from those that prevailed in these six clinical trials.
 Similarly, the cited frequencies cannot be compared with figures obtained
from other clinical investigators involving related drug products and uses,
since each group of drug trials was conducted under a different set of conditions.
 However, the cited figures provide the physician with a basis of estimating
the relative contribution of drug and nondrug factors to the incidence of
side effects in the population studied.</paragraph><table ID="table_1" width="100%"><caption>Incidence of Adverse Experiences in Placebo-Controlled
Clinical Trials (Percentage of Patients Reporting)</caption>
<colgroup>
<col width="40%" />
<col width="29%" />
<col width="28%" />
</colgroup>
<thead>
<tr><td><content styleCode="bold">Body System/    <br />Adverse Event*</content></td><td align="center"><content styleCode="bold">ProSom    <br />(N=685)</content></td><td align="center"><content styleCode="bold">Placebo    <br />(N=433)</content></td></tr>
</thead>
<tfoot>
<tr><td colspan="3"><paragraph styleCode="Footnote">*&#160;&#160;
Events reported by at least 1% of ProSom patients.</paragraph></td></tr>
</tfoot>
<tbody>
<tr><td>Body as a Whole</td><td align="center" /><td align="center" /></tr>
<tr><td>&#160;&#160;&#160;Headache</td><td align="center">16</td><td align="center">27</td></tr>
<tr><td>&#160;&#160;&#160;Asthenia</td><td align="center">11</td><td align="center">8</td></tr>
<tr><td>&#160;&#160;&#160;Malaise</td><td align="center">5</td><td align="center">5</td></tr>
<tr><td>&#160;&#160;&#160;Lower extremity&#160;pain</td><td align="center">3</td><td align="center">2</td></tr>
<tr><td>&#160;&#160;&#160;Back pain</td><td align="center">2</td><td align="center">2</td></tr>
<tr><td>&#160;&#160;&#160;Body pain</td><td align="center">2</td><td align="center">2</td></tr>
<tr><td>&#160;&#160;&#160;Abdominal pain</td><td align="center">1</td><td align="center">2</td></tr>
<tr><td>&#160;&#160;&#160;Chest pain</td><td align="center">1</td><td align="center">1</td></tr>
<tr><td>&#160;&#160;&#160;Digestive System</td><td align="center" /><td align="center" /></tr>
<tr><td>&#160;&#160;&#160;Nausea</td><td align="center">4</td><td align="center">5</td></tr>
<tr><td>&#160;&#160;&#160;Dyspepsia</td><td align="center">2</td><td align="center">2</td></tr>
<tr><td>Musculoskeletal System</td><td align="center" /><td align="center" /></tr>
<tr><td>&#160;&#160;&#160;Stiffness</td><td align="center">1</td><td align="center">-</td></tr>
<tr><td>Nervous System</td><td align="center" /><td align="center" /></tr>
<tr><td>&#160;&#160;&#160;Somnolence</td><td align="center">42</td><td align="center">27</td></tr>
<tr><td>&#160;&#160;&#160;Hypokinesia</td><td align="center">8</td><td align="center">4</td></tr>
<tr><td>&#160;&#160;&#160;Nervousness</td><td align="center">8</td><td align="center">11</td></tr>
<tr><td>&#160;&#160;&#160;Dizziness</td><td align="center">7</td><td align="center">3</td></tr>
<tr><td>&#160;&#160;&#160;Coordination abnormal</td><td align="center">4</td><td align="center">1</td></tr>
<tr><td>&#160;&#160;&#160;Hangover</td><td align="center">3</td><td align="center">2</td></tr>
<tr><td>&#160;&#160;&#160;Confusion</td><td align="center">2</td><td align="center">-</td></tr>
<tr><td>&#160;&#160;&#160;Depression</td><td align="center">2</td><td align="center">3</td></tr>
<tr><td>&#160;&#160;&#160;Dream abnormal</td><td align="center">2</td><td align="center">2</td></tr>
<tr><td>&#160;&#160;&#160;Thinking abnormal</td><td align="center">2</td><td align="center">1</td></tr>
<tr><td>Respiratory System</td><td align="center" /><td align="center" /></tr>
<tr><td>&#160;&#160;&#160;Cold symptoms</td><td align="center">3</td><td align="center">5</td></tr>
<tr><td>&#160;&#160;&#160;Pharyngitis</td><td align="center">1</td><td align="center">2</td></tr>
<tr><td>Skin and Appendages</td><td align="center" /><td align="center" /></tr>
<tr><td>&#160;&#160;&#160;Pruritus</td><td align="center">1</td><td align="center">-</td></tr>
</tbody>
</table></text>
<effectiveTime value="20060616" />
</section>
</component>
<component>
<section>
<id root="2B8C0AD6-7191-CE2D-0735-39C176B47C79" />
<title mediaType="text/x-hl7-title+xml">Other Adverse Events</title>
<text><paragraph>During clinical trials conducted by Abbott, some
of which were not placebo&#160;&#8722;&#160;controlled, ProSom was administered
to approximately 1300 patients.  Untoward events associated with this exposure
were recorded by clinical investigators using terminology of their own choosing.
 To provide a meaningful estimate of the proportion of individuals experiencing
adverse events, similar types of untoward events must be grouped into a smaller
number of standardized event categories.  In the tabulations that follow,
a standard COSTART dictionary terminology has been used to classify reported
adverse events.  The frequencies presented, therefore, represent the proportion
of the 1277 individuals exposed to ProSom who experienced an event of the
type cited on at least one occasion while receiving ProSom.  All reported
events are included except those already listed in the previous table, those
COSTART terms too general to be informative, and those events where a drug
cause was remote.  Events are further classified within body system categories
and enumerated in order of decreasing frequency using the following definitions:
 frequent adverse events are defined as those occurring on one or more occasions
in at least 1/100 patients; infrequent adverse events are those occurring
in 1/100 to 1/1000 patients; rare events are those occurring in less than
1/1000 patients.  It is important to emphasize that, although the events reported
did occur during treatment with ProSom, they were not necessarily caused by
it.</paragraph></text>
<effectiveTime value="20060616" />
<component>
<section>
<id root="59FFAEBD-552D-B0F0-A7F4-95B1970480BC" />
<title mediaType="text/x-hl7-title+xml">Body as a Whole</title>
<text><paragraph /></text>
<effectiveTime value="20060616" />
<component>
<section>
<id root="A9061E57-21D5-E59F-6E20-4E93E69D9F29" />
<title mediaType="text/x-hl7-title+xml">Infrequent</title>
<text><paragraph>allergic reaction, chills, fever, neck pain,
upper extremity pain</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
<component>
<section>
<id root="5864262C-FFA5-6E03-1222-8E2FF80D7AA4" />
<title mediaType="text/x-hl7-title+xml">Rare</title>
<text><paragraph>edema, jaw pain, swollen breast.</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
</section>
</component>
<component>
<section>
<id root="30150452-AD89-2E05-9D1A-C8475BF62589" />
<title mediaType="text/x-hl7-title+xml">Cardiovascular System</title>
<text><paragraph /></text>
<effectiveTime value="20060616" />
<component>
<section>
<id root="7AE51B2F-2F8D-6FDC-1B62-9870D79849CD" />
<title mediaType="text/x-hl7-title+xml">Infrequent</title>
<text><paragraph>flushing, palpitation</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
<component>
<section>
<id root="9BC31C1C-108F-9DDC-B41B-2BA242FFC0A7" />
<title mediaType="text/x-hl7-title+xml">Rare</title>
<text><paragraph>arrhythmia, syncope.</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
</section>
</component>
<component>
<section>
<id root="CE4084A4-CC97-3A25-DB5F-A382E44F9B62" />
<title mediaType="text/x-hl7-title+xml">Digestive System</title>
<text><paragraph /></text>
<effectiveTime value="20060616" />
<component>
<section>
<id root="B4C5AA72-4EE1-4E19-B807-E214ED80B099" />
<title mediaType="text/x-hl7-title+xml">Frequent</title>
<text><paragraph>constipation, dry mouth</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
<component>
<section>
<id root="A0CD4E63-724C-7DFF-77CC-57D2546080EB" />
<title mediaType="text/x-hl7-title+xml">Infrequent</title>
<text><paragraph>decreased appetite, flatulence, gastritis, increased
appetite, vomiting</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
<component>
<section>
<id root="C5E83EB4-D6CA-9C3A-EF7B-9F5C5464EB8E" />
<title mediaType="text/x-hl7-title+xml">Rare</title>
<text><paragraph>enterocolitis, melena, ulceration of the mouth.</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
</section>
</component>
<component>
<section>
<id root="88C8396A-9098-EFC2-E521-DF6024B99C10" />
<title mediaType="text/x-hl7-title+xml">Endocrine System</title>
<text><paragraph /></text>
<effectiveTime value="20060616" />
<component>
<section>
<id root="1ACA1FCB-FD76-E0F4-2308-88730D1599B3" />
<title mediaType="text/x-hl7-title+xml">Rare</title>
<text><paragraph>thyroid nodule.</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
</section>
</component>
<component>
<section>
<id root="3E7F1A6C-E90E-0DEC-F28A-3423240DB208" />
<title mediaType="text/x-hl7-title+xml">Hematologic and Lymphatic System</title>
<text><paragraph /></text>
<effectiveTime value="20060616" />
<component>
<section>
<id root="54F4592E-0858-6FBA-E9A1-E32531B7A53A" />
<title mediaType="text/x-hl7-title+xml">Rare</title>
<text><paragraph>leukopenia, purpura, swollen lymph nodes.</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
</section>
</component>
<component>
<section>
<id root="AA535CDB-FF1D-748C-E91A-8C8569CC0F9D" />
<title mediaType="text/x-hl7-title+xml">Metabolic/Nutritional Disorders</title>
<text><paragraph /></text>
<effectiveTime value="20060616" />
<component>
<section>
<id root="97CD31EC-2455-C10A-DF3C-584FD72F95D0" />
<title mediaType="text/x-hl7-title+xml">Infrequent</title>
<text><paragraph>thirst</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
<component>
<section>
<id root="F5C6CCE6-329B-0207-AF35-19E51679ACA6" />
<title mediaType="text/x-hl7-title+xml">Rare</title>
<text><paragraph>increased SGOT, weight gain, weight loss.</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
</section>
</component>
<component>
<section>
<id root="B6E16FC1-2DCB-50C7-C930-18A6B2C1DADB" />
<title mediaType="text/x-hl7-title+xml">Musculoskeletal System</title>
<text><paragraph /></text>
<effectiveTime value="20060616" />
<component>
<section>
<id root="16829EA9-A98A-45F2-E33B-89D3D487FFF0" />
<title mediaType="text/x-hl7-title+xml">Infrequent</title>
<text><paragraph>arthritis, muscle spasm, myalgia</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
<component>
<section>
<id root="2BD2E68B-AEFF-984B-4405-E7B71493B9D0" />
<title mediaType="text/x-hl7-title+xml">Rare</title>
<text><paragraph>arthralgia.</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
</section>
</component>
<component>
<section>
<id root="CC9C26F9-6383-37F8-0308-398804C047A6" />
<title mediaType="text/x-hl7-title+xml">Nervous System</title>
<text><paragraph /></text>
<effectiveTime value="20060616" />
<component>
<section>
<id root="11B20797-D10D-8551-38F0-7A7B2F3D4854" />
<title mediaType="text/x-hl7-title+xml">Frequent</title>
<text><paragraph>anxiety</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
<component>
<section>
<id root="FC9209A7-7C33-D920-87D1-F69D29E4FC87" />
<title mediaType="text/x-hl7-title+xml">Infrequent</title>
<text><paragraph>agitation, amnesia, apathy, emotional lability,
euphoria, hostility, paresthesia, seizure, sleep disorder, stupor, twitch</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
<component>
<section>
<id root="C59D18D7-962B-CF7F-E69E-DED585C91C08" />
<title mediaType="text/x-hl7-title+xml">Rare</title>
<text><paragraph>ataxia, circumoral paresthesia, decreased libido,
decreased reflexes, hallucinations, neuritis, nystagmus, tremor.</paragraph><paragraph>Minor changes in EEG patterns, usually low-voltage fast
activity, have been observed in patients during ProSom therapy or withdrawal
and are of no known clinical significance.</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
</section>
</component>
<component>
<section>
<id root="4FA70C5F-B018-A1D9-284A-EAACA23EC57E" />
<title mediaType="text/x-hl7-title+xml">Respiratory System</title>
<text><paragraph /></text>
<effectiveTime value="20060616" />
<component>
<section>
<id root="EDDB5085-0E6E-23C2-A3A4-26B91382644B" />
<title mediaType="text/x-hl7-title+xml">Infrequent</title>
<text><paragraph>asthma, cough, dyspnea, rhinitis, sinusitis</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
<component>
<section>
<id root="BF35D372-FEA4-3ECB-C669-279FE62477F1" />
<title mediaType="text/x-hl7-title+xml">Rare</title>
<text><paragraph>epistaxis, hyperventilation, laryngitis.</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
</section>
</component>
<component>
<section>
<id root="4CE7C63D-7587-42BE-05BC-C84402C85352" />
<title mediaType="text/x-hl7-title+xml">Skin and Appendages</title>
<text><paragraph /></text>
<effectiveTime value="20060616" />
<component>
<section>
<id root="5C39C1FA-0149-9DCB-E78F-53A81469B3F8" />
<title mediaType="text/x-hl7-title+xml">Infrequent</title>
<text><paragraph>rash, sweating, urticaria</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
<component>
<section>
<id root="C22A0CAC-5C80-91FA-81B6-46A08A8AB3B5" />
<title mediaType="text/x-hl7-title+xml">Rare</title>
<text><paragraph>acne, dry skin.</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
</section>
</component>
<component>
<section>
<id root="7CC4A82B-4117-D992-794D-A821B08F7010" />
<title mediaType="text/x-hl7-title+xml">Special Senses</title>
<text><paragraph /></text>
<effectiveTime value="20060616" />
<component>
<section>
<id root="022CE2D7-3C70-AAB3-222A-FACBCD59F620" />
<title mediaType="text/x-hl7-title+xml">Infrequent</title>
<text><paragraph>abnormal vision, ear pain, eye irritation, eye
pain, eye swelling, perverse taste, photophobia, tinnitus</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
<component>
<section>
<id root="2805AFD2-3A4A-4741-EDF0-14669AB08621" />
<title mediaType="text/x-hl7-title+xml">Rare</title>
<text><paragraph>decreased hearing, diplopia, scotomata.</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
</section>
</component>
<component>
<section>
<id root="EDFB96E7-BD0F-EB95-B4DF-70AB426C12E2" />
<title mediaType="text/x-hl7-title+xml">Urogenital System</title>
<text><paragraph /></text>
<effectiveTime value="20060616" />
<component>
<section>
<id root="A728B507-0152-7ABB-C518-9B59B1C91E14" />
<title mediaType="text/x-hl7-title+xml">Infrequent</title>
<text><paragraph>frequent urination, menstrual cramps, urinary
hesitancy, urinary urgency, vaginal discharge/itching</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
<component>
<section>
<id root="FE08183E-E062-256A-6702-FA86B7B2E105" />
<title mediaType="text/x-hl7-title+xml">Rare</title>
<text><paragraph>hematuria, nocturia, oliguria, penile discharge,
urinary incontinence.</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
</section>
</component>
<component>
<section>
<id root="CFF8DEA7-82C1-5F66-831C-54A9059A9A29" />
<title mediaType="text/x-hl7-title+xml">Postintroduction Reports</title>
<text><paragraph>Voluntary reports of non-US postmarketing experience
with estazolam have included rare occurrences of photosensitivity, Stevens-Johnson
syndrome, and agranulocytosis.  Because of the uncontrolled nature of these
spontaneous reports, a causal relationship to estazolam treatment has not
been determined.</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
</section>
</component>
</section>
</component>
<component>
<section>
<id root="FA5C7D5D-344E-9E1C-421C-38DF76B0916C" />
<code code="42227-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Drug Abuse and Dependence" />
<title mediaType="text/x-hl7-title+xml">DRUG ABUSE AND DEPENDENCE</title>
<text />
<effectiveTime value="20060616" />
<component>
<section>
<id root="12BF32A4-2014-E1A7-7A35-9EC9CC41E341" />
<code code="34085-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Controlled Substance section" />
<title mediaType="text/x-hl7-title+xml">Controlled Substance</title>
<text><paragraph>ProSom tablets are a controlled substance in Schedule
IV.</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
<component>
<section>
<id root="463D39FB-F87F-7797-7FB5-C03473E3BBCD" />
<title mediaType="text/x-hl7-title+xml">Abuse and Dependence</title>
<text><paragraph>Withdrawal symptoms similar to those noted with
sedatives/hypnotics and alcohol have occurred following the abrupt discontinuation
of drugs in the benzodiazepine class.  The symptoms can range from mild dysphoria
and insomnia to a major syndrome that may include abdominal and muscle cramps,
vomiting, sweating, tremors, and convulsions.</paragraph><paragraph>Although
withdrawal symptoms are more commonly noted after the discontinuation of higher
than therapeutic doses of benzodiazepines, a proportion of patients taking
benzodiazepines chronically at therapeutic doses may become physically dependent
on them.  Available data, however, cannot provide a reliable estimate of the
incidence of dependency or the relationship of the dependency to dose and
duration of treatment.  There is some evidence to suggest that gradual reduction
of dosage will attenuate or eliminate some withdrawal phenomena.  In most
instances, withdrawal phenomena are relatively mild and transient; however,
life-threatening events (e.g., seizures, delirium, etc.) have been reported.</paragraph><paragraph>Gradual withdrawal is the preferred course for any patient
taking benzodiazepines for a prolonged period.  Patients with a history of
seizures, regardless of their concomitant antiseizure drug therapy, should
not be withdrawn abruptly from benzodiazepines.</paragraph><paragraph>Individuals
with a history of addiction to or abuse of drugs or alcohol should be under
careful surveillance when receiving benzodiazepines because of the risk of
habituation and dependence to such patients.</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
</section>
</component>
<component>
<section>
<id root="C5F3EFC5-8E3B-FC09-5CA3-792BDD5B9E37" />
<code code="34088-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="OVERDOSAGE section" />
<title mediaType="text/x-hl7-title+xml">OVERDOSAGE</title>
<text><paragraph>As with other benzodiazepines, experience with ProSom
indicates that manifestations of overdosage include somnolence, respiratory
depression, confusion, impaired coordination, slurred speech, and ultimately,
coma.  Patients have recovered from overdosage as high as 40 mg.  As in the
management of intentional overdose with any drug, the possibility should be
considered that multiple agents may have been taken.</paragraph><paragraph>Gastric
evacuation, either by the induction of emesis, lavage, or both, should be
performed immediately.  Maintenance of adequate ventilation is essential.
 General supportive care, including frequent monitoring of the vital signs
and close observation of the patient, is indicated.  Fluids should be administered
intravenously to maintain blood pressure and encourage diuresis.  The value
of dialysis in treatment of benzodiazepine overdose has not been determined.
 The physician may wish to consider contacting a Poison Control Center for
up-to-date information on the management of hypnotic drug product overdose.</paragraph><paragraph>Flumazenil, a specific benzodiazepine receptor antagonist,
is indicated for the complete or partial reversal of the sedative effects
of benzodiazepines and may be used in situations when an overdose with a benzodiazepine
is known or suspected.  Prior to the administration of flumazenil, necessary
measures should be instituted to secure airway, ventilation, and intravenous
access.  Flumazenil is intended as an adjunct to, not as a substitute for,
proper management of benzodiazepine overdose.  Patients treated with flumazenil
should be monitored for resedation, respiratory depression, and other residual
benzodiazepine effects for an appropriate period after treatment.  <content styleCode="bold">The prescriber should be aware of a risk of seizure in association
with flumazenil treatment, particularly in long&#160;&#8722;&#160;term benzodiazepine
users and in cyclic antidepressant overdose.</content>  The complete flumazenil
package insert including <content styleCode="bold">CONTRAINDICATIONS</content>, <content styleCode="bold">WARNINGS</content>, and <content styleCode="bold">PRECAUTIONS </content> should be consulted prior to use.</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
<component>
<section>
<id root="74F40C87-B547-5238-9317-9321BF353ABD" />
<code code="34068-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DOSAGE AND ADMINISTRATION section" />
<title mediaType="text/x-hl7-title+xml">DOSAGE AND ADMINISTRATION</title>
<text><paragraph>The recommended initial dose for adults is 1 mg at
bedtime; however, some patients may need a 2 mg dose.  In healthy elderly
patients, 1 mg is also the appropriate starting dose, but increases should
be initiated with particular care.  In small or debilitated older patients,
a starting dose of 0.5 mg, while only marginally effective in the overall
elderly population, should be considered.</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
<component>
<section>
<id root="364082AD-3508-9D91-7313-CFF75905BF06" />
<code code="34069-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="HOW SUPPLIED section" />
<title mediaType="text/x-hl7-title+xml">HOW SUPPLIED</title>
<text />
<effectiveTime value="20060616" />
<component>
<section>
<id root="BC7C1EE5-76B9-54C5-F946-35EC1A9E83F0" />
<title mediaType="text/x-hl7-title+xml">ProSom tablets are scored tablets supplied as</title>
<text><paragraph>ProSom Tablets 1 mg white tablets bearing the Abbott
logo and UC (Abbo-Code).  Bottles of 100 (<content styleCode="bold">NDC</content> 0074-3735-13)</paragraph><paragraph>ProSom Tablets 2 mg pink tablets bearing the Abbott logo
and UD (Abbo-Code).  Bottles of 100 (<content styleCode="bold">NDC</content> 0074-3736-13).</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
<component>
<section>
<id root="5D44B76A-BFBE-2F2F-1C32-524011F19F07" />
<title mediaType="text/x-hl7-title+xml">Recommended Storage</title>
<text><paragraph>Store below 86&#176;F (30&#176;C).</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
</section>
</component>
<component>
<section>
<id root="36F9C614-AFD4-E6EC-686A-D63711D7B18C" />
<title mediaType="text/x-hl7-title+xml" />
<text><paragraph>Mfd. by Abbott Pharmaceuticals PR Ltd.<br />Barceloneta, PR
00617</paragraph><paragraph>for</paragraph><paragraph>Abbott Laboratories, North Chicago, IL, 60064, USA							</paragraph></text>
<effectiveTime value="20060616" />
</section>
</component>
</structuredBody>
</component>
</document>
